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Persistent induction of type 1 interferon (IFN) is associated with human immunodeficiency virus type 1 (HIV-1)
infection. We report here that the pathogenic HIV strain R3A (HIV-R3A) induced high levels of type 1 IFN, while the
nonpathogenic HIV-R3B showed no significant induction in human fetal thymus organ culture (HFTOC). We found that
IFN contributed to the depletion of human T cells by HIV-R3A in a fusion-independent fashion. The R3B recombinant
with the R3A Env V1V2 domain (R3B/A-V1V2) was able to induce type 1 IFN, which contributed to the increased
depletion of T cells. Therefore, type 1 IFN induction plays a significant role in HIV-induced T cell depletion in the human
thymus.
Pathogenic infections of humans and rhesus macaques by
human immunodeficiency virus (HIV) and simian immunode-
ficiency virus (SIV), respectively, are characterized by gener-
alized immune activation and progressive CD4 T cell depletion
(3, 23). It has been proposed that chronic activation of inter-
feron (IFN) production may play a role in CD4 T cell depletion
and AIDS progression (1, 5, 8–10). Although in vitro studies
have demonstrated that type 1 IFN can suppress HIV type 1
(HIV-1) viral replication, several in vivo studies and clinical
trials have engendered mixed results in the efficacy of alpha
IFN (IFN-) treatment and control of HIV-1 (19–21). This is
further complicated by recent reports that IFN- produced by
plasmacytoid dendritic cells (pDC) may mediate CD4 T cell
depletion (5–7). The study of the role of type 1 IFN in HIV-1
pathogenesis is greatly limited by the lack of a relevant exper-
imental model for HIV infection and pathogenesis. We have
shown that human fetal thymus organ culture (HFTOC)
closely models HIV infection and pathogenesis in vivo (15) in
terms of viral replication and CD4 T cell depletion (2, 13, 16,
18). In addition, pathogenic HIV-1 infection in HFTOC is
associated with IFN induction (4, 11, 12).
HIV strain R3A (HIV-R3A) (but not HIV-R3B) is highly
pathogenic in the human fetal thymus organ culture (HFTOC)
model or in SCID-hu Thy/Liv mice in vivo (14, 15, 17, 22).
When type 1 interferon (IFN) was measured, IFN was highly
induced in HFTOC infected with R3A but not with R3B (Fig.
1A). When human IFN-/ were neutralized with a specific
neutralizing antibody (nAb), almost all the type 1 IFN was
blocked (Fig. 1B). We evaluated the role of type 1 IFN-/ in
HIV-R3A-mediated pathogenesis in HFTOC. Consistent with
the antiviral activity of type 1 IFN, neutralization of IFN-/
with the neutralizing antibody (nAb) significantly enhanced
HIV-1 replication in HFTOC (data not shown and see Fig. 3).
Interestingly, blocking IFN-/ with nAb alone only slightly
prevented HIV-R3A-mediated T cell depletion. Furthermore,
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FIG. 1. HIV-R3A preferentially induces type I IFN that significantly
contributes to CD4 T cell depletion. (A) Type 1 IFN induction was measured
in HFTOC infected with HIV-R3A and HIV-R3B. Supernatants were har-
vested 24 h after infection for detection by type 1 IFN bioassay. (B) HFTOC
was infected with HIV-R3A, and supernatant was treated with control rabbit
IgG antibody or rabbit anti-human IFN- neutralizing antibodies (nAb)
during the IFN bioassay (neutralizing antibodies against human IFN- and -
were obtained from the Biodefense and Emerging Infections Resources Re-
pository, BEI Resources). (C, D) HFTOC was infected with HIV-R3A in the
presence or absence of IFN-/ neutralizing antibodies (nAb), fusion inhib-
itor C34, or both IFN-/ nAb and C34. IFN nAb (neutralizing antibodies
against human IFN- and - were obtained from the Biodefense and Emerg-
ing Infections Resources Repository, BEI Resources) or control antibody was
added to HIV-R3A alone at 0 days postinfection (dpi), and the fusion inhib-
itor C34 was added at 5 dpi. HFTOC was harvested at 8 dpi to measure CD4
thymocyte depletion by the percentage of CD4 T cells (C) or the total
number of CD4 T cells per HFTOC fragment. Error bars indicate standard
deviations (n  3). , P  0.05.
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when HIV-mediated fusion was also inhibited with the fusion
inhibitor C34 during peak viral replication, IFN nAb further
significantly rescued human thymocytes (Fig. 1C and D). We
conclude that induction of IFN-/ by HIV-R3A infection
contributes to its highly pathogenic activity, at least partly via a
fusion-independent mechanism of CD4 T cell killing.
We mapped the R3A Env domains that contributed to the
induction of type 1 IFN with Env recombinants between R3A
and R3B. Although the R3B recombinant with the R3A Env
V1V2 domain (R3B/A-V1V2) with a defective Nef gene
showed pathogenic activity similar to that of HIV-R3B (14, 15,
17, 22), we studied the relative pathogenicity of the R3B/A-
V1V2 recombinant in comparison to R3A and R3B when their
Nef genes were restored. When tested in the HFTOC model,
the R3B/A-V1V2 recombinant demonstrated higher IFN in-
duction activity than HIV-R3B (Fig. 2A). Interestingly, R3B/
A-V1V2 also showed significantly higher replication than HIV-
R3B in HFTOC, even though it induced higher levels of IFN
(Fig. 2B). When human CD4 thymocyte depletion was mea-
sured, R3B/A-V1V2 also showed elevated pathogenic activity
compared to that of R3B (Fig. 2C and D). Therefore, the
V1V2 domain of R3A is one of the R3A pathogenic determi-
nants in the presence of a functional Nef gene. Since R3B/A-
V1V2 still showed lower pathogenic activity than R3A, R3A
Env encodes additional pathogenic determinants, such as the
high fusion activity (17, 22).
We reasoned that the pathogenic activity of the R3B/A-
V1V2 recombinant should be more dependent on the type I
IFN activity. We thus evaluated the role of type 1 IFN in
HIV-R3B/A-V1V2-mediated pathogenesis in HFTOC by
blocking IFN with a neutralizing antibody (nAb). Consistent
with the antiviral activity of type 1 IFN, neutralization of IFN
significantly enhanced HIV-1 replication in HFTOC (Fig. 3A).
Interestingly, blockage of IFN almost completely prevented
R3B/A-V1V2-mediated T cell depletion even with elevated
HIV-1 replication (Fig. 3B). With a weak fusogenic activity of
R3B Env, fusion inhibitor C34 did not show a significant pro-
tective effect on CD4 T cell depletion by R3B/A-V1V2. We
conclude that induction of type 1 IFN by the R3A-V1V2 do-
main contributes to its high pathogenic activity (14).
We have previously reported that Env-mediated fusion plays
a major role in CD4 depletion during infection of HFTOC
with HIV-R3A (17). We found here that R3A-induced IFN-
/ led to fusion-independent CD4 T cell depletion. IFN neu-
tralizing antibodies significantly inhibited CD4 T cell deple-
tion, even in the presence of higher levels of HIV-1 replication.
Thus, type 1 IFN that provides an antiviral response also con-
tributes to the depletion of CD4 T cells by HIV-1 infection. In
HFTOC infected with the R3B/A-V1V2 recombinant, which
encodes the weak R3B fusion activity but the strong IFN in-
duction of R3A-V1V2, type 1 IFN seemed to be the major
determinant of CD4 depletion. We conclude that the patho-
FIG. 2. The R3A V1V2 domain confers both enhanced IFN induction and pathogenesis in HFTOC. (A) HFTOC fragments were infected with
R3A, R3B, and the R3B/A-V1V2 chimera recombinant. Supernatants were harvested at 24 h postinfection and analyzed by IFN bioassay. Error
bars indicate standard deviations (n  3). (B, C) HFTOC was infected with R3A, R3B, and the R3B/A-V1V2 recombinant. Viral replication
(B) was measured by p24 enzyme-linked immunosorbent assay (ELISA), and CD4 thymocyte depletion (C) was measured by FACS analysis at
8 dpi. Error bars indicate standard deviations. , P  0.05.
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genic HIV-1 Env encodes multiple, pathogenic determinants,
including separable IFN induction activity and high fusion
activity (14, 17, 22). As an in vitro model, the HFTOC has its
limitation of generalizing the findings in other lymphoid organs
and in an immunocompetent host. It will be important to
further study the relative pathogenicity and IFN induction by
R3A, R3B, and the chimeric recombinants in the humanized
mouse models with a functional human immune system (24).
We will also extend the findings in HIV-infected patients and
in SIV-infected monkeys in future studies.
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